Indi Molecular Inc.'s protein-catalyzed capture platform produces synthetic peptides that could be used as in vivo imaging agents and in vitro diagnostics when low target immunogenicity or suboptimal pharmacokinetics limit the utility of mAbs.

Despite their limitations, mAbs are still the platform of choice for protein recognition tasks because peptide-based approaches do not consistently yield agents with antibody-like affinity and specificity.